AMAG Pharmaceuticals Net debt/EBITDA
Cos'è Net debt/EBITDA di AMAG Pharmaceuticals?
Net debt/EBITDA di AMAG Pharmaceuticals, Inc. è -5.97
Qual è la definizione di Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA di aziende nel Health Care settore su NASDAQ rispetto a AMAG Pharmaceuticals
Cosa fa AMAG Pharmaceuticals?
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. Its products include Intrarosa, Vyleesi, Makena, CBR, Feraheme, and MuGard. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.
Aziende con net debt/ebitda simili a AMAG Pharmaceuticals
- XLMedia PLC ha Net debt/EBITDA di -5.99
- SEI Investments Co ha Net debt/EBITDA di -5.99
- Beng Soon Mach Hldg Ltd ha Net debt/EBITDA di -5.98
- Pacific Silk Road Resources ha Net debt/EBITDA di -5.98
- Wipro ha Net debt/EBITDA di -5.98
- MainStreet Bancshares Inc ha Net debt/EBITDA di -5.97
- AMAG Pharmaceuticals ha Net debt/EBITDA di -5.97
- Eildon Capital Fund ha Net debt/EBITDA di -5.97
- CYREN Ltd ha Net debt/EBITDA di -5.97
- Evolis SA ha Net debt/EBITDA di -5.95
- Industria de Diseño Textil SA ha Net debt/EBITDA di -5.95
- VersaBank ha Net debt/EBITDA di -5.94
- 3P Learning ha Net debt/EBITDA di -5.94